ALVO Stock Analysis: Buy, Sell, or Hold?

ALVO - Alvotech Ordinary Shares

Biological Products, (No Diagnostic Substances)
$3.70
0.05 (1.37%) β–²
5d: -12.74%
30d: +9.47%
90d: +11.11%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 12, 2026

Get Alerted When ALVO Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

πŸ’‘
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ALVO is down 12.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
See Forward Earnings Fair Value & Price Prediction β†’

In-depth Analysis How we analyze

Valuation Analysis: ALVO is currently trading at $3.70, which is considered fair relative to its 30-day fair value range of $3.26 to $4.03. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.7) compared to its historical average (15.7). At these levels, the market is pricing in 9.5% annual earnings growth.

Technical Outlook: Technically, ALVO is in a downtrend. The price is currently testing key support at $3.64. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.83 (+273.9%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position FAIR
Historical Trading Range $3.26 - $4.03
Company Quality Score 50/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 75.7%

All Signals

  • NEUTRAL: Price in fair range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 273.9% below Wall St target ($13.83)
  • BULLISH: Expecting earnings turnaround to 9.5% growth with -20.2% revenue growth
  • WARNING: Recommendation downgraded due to -12.7% 5-day decline - wait for stabilization

Trading Range Analysis

30-Day Trading Range $3.26 - $4.03
Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $3.64
Resistance Level $4.59
Current Trend Downtrend
Technical data as of Jun 23, 2026

Fundamental Context

Forward P/E (Next Year Est.) 20.67
Wall Street Target $13.83 (+273.9%)
Revenue Growth (YoY) -20.2%
Earnings Growth (YoY) -99.0%
Profit Margin -14.4%
Valuation Premium vs History +9.5% premium
PE vs Historical 20.7 vs 15.7 STRETCHED
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +9.5% (market-implied from PE analysis)
1-Year Target $4.05 (+10%)
2-Year Target $4.44 (+20%)
3-Year Target $4.86 (+31%)
3-Yr Target (if PE normalizes) (PE: 21β†’16) PE COMPRESSION $3.69 (0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 21.8, Growth: 216.8%) $13.16 (+256%)
Base: (SPY PE: 20.7, Growth: 216.8%) $12.49 (+238%)
Bear: (PE: 15.7, Growth: 216.8%) $9.48 (+156%)
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: June 24, 2026 2:36 AM ET
Data refreshes hourly during market hours. Next update: 3:36 AM
πŸ”₯ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for ALVO.

Create Free Account

Already have an account? Log In

Top Rated Drug Manufacturers - Specialty & Generic Stocks

Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NBIX
Neurocrine Biosciences I…
STRONG BUY
25 analysts
$194 60 BUY
LNTH
Lantheus Holdings Inc
STRONG BUY
13 analysts
$105 64 BUY
BCRX
BioCryst Pharmaceuticals…
STRONG BUY
12 analysts
$21 67 BUY
ZTS
Zoetis Inc
BUY
20 analysts
$125 58 HOLD
UTHR
United Therapeutics Corp…
STRONG BUY
15 analysts
$665 57 HOLD

More Analysis for ALVO

ALVO Technical Chart ALVO Price Prediction ALVO Earnings Date ALVO Investment Advisor ALVO Fair Price Analyzer ALVO Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals